AEON Biopharma, Inc. Forecasted to Post Q1 2025 Earnings of ($0.29) Per Share (NASDAQ:AEON)

AEON Biopharma, Inc. (NASDAQ:AEON) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of AEON Biopharma in a report released on Wednesday, April 17th. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of ($0.29) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for AEON Biopharma’s current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for AEON Biopharma’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.32) EPS and Q4 2025 earnings at ($0.24) EPS.

AEON Biopharma (NASDAQ:AEON) last posted its quarterly earnings data on Friday, March 29th. The company reported ($0.71) earnings per share for the quarter.

AEON Biopharma Price Performance

AEON stock opened at $6.54 on Thursday. The business’s fifty day moving average is $10.64 and its 200-day moving average is $7.78. AEON Biopharma has a twelve month low of $3.37 and a twelve month high of $17.17.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Atalaya Capital Management LP acquired a new stake in shares of AEON Biopharma in the third quarter valued at about $19,827,000. Formidable Asset Management LLC bought a new stake in AEON Biopharma during the third quarter worth $360,000. Vanguard Group Inc. bought a new position in AEON Biopharma during the third quarter worth about $1,085,000. Finally, Northern Trust Corp lifted its position in shares of AEON Biopharma by 53.4% in the fourth quarter. Northern Trust Corp now owns 49,819 shares of the company’s stock valued at $359,000 after buying an additional 17,341 shares during the last quarter. Institutional investors and hedge funds own 22.78% of the company’s stock.

About AEON Biopharma

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.